Previsioni

Il prezzo obiettivo medio degli analisti è 88,68 € (+14,06%). La mediana è 88,07 € (+13,27%).

Acquista	33
Mantieni	16
Vendi	0

Notizie Vai al feed delle notizie

CMS guideline on TAVR reimbursement strengthens Edwards Lifesciences

US agency CMS has published a final national reimbursement guideline for TAVR that also provides reimbursement for asymptomatic aortic stenosis, thereby strengthening the TAVR market. Stifel views the decision as positive for Edwards Lifesciences and expects it to support the long-term revenue growth forecast of over 10%. The guideline retains case volume requirements and the role of the heart team including cardiac surgeons, but allows asynchronous chart review and requires only a single TAVR operator in the room, which increases procedural efficiency. CMS also announced a national review of reimbursement for TAVR in aortic regurgitation, expected to conclude on June 8, 2027. » Altro su de.investing.com
Edwards Lifesciences noted as leader in TAVR growth by Aristotle Value fund

Aristotle Capital's Value Equity Fund highlighted Edwards Lifesciences for its leadership in transcatheter aortic valve replacement (TAVR) and structural heart therapies, citing the procedure's role in expanding patient eligibility and market adoption. The fund referenced Edwards' market position and recent stock range, with shares around $90.78 and a market cap near $51.8 billion. The mention came in the fund's Q2 2026 letter, which contrasted its own underperformance versus AI-driven index gains while still listing Edwards among notable holdings. 68 hedge funds held Edwards at the end of Q1 2026, up from 64 the prior quarter. » Altro su finance.yahoo.com
Edwards Lifesciences reaches new 52-week high at 92.94 USD

Shares of Edwards Lifesciences rose to a 52-week high of 92.94 USD and are currently trading just below that level; year-to-date the stock is up about 20.09%. The company trades at a P/E ratio of 50.01 and is considered overvalued by InvestingPro. At the New York Valves 2026 conference Edwards presented data from the PROGRESS study on TAVR, and the U.S. government proposed a National Coverage Decision memorandum for TAVR, which analysts view positively. Leerink reiterated "Market Perform" with a price target of 87 USD, TD Cowen raised its target to 104 USD; Theodora Mistras was also appointed as the new chief financial officer. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Edwards Lifesciences ha registrato ricavi pari a 1,53 Mld € e un utile netto di 211,96 Mln €

(EUR)	giugno 2026	YoY
Ricavi	1,53 Mld	17,35%
Utile lordo	1,18 Mld	17,24%
Utile netto	211,96 Mln	24,25%
EBITDA	455,19 Mln	34,06%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	43,05 Mld €
Numero di azioni	575,8 Mln
Massimo/minimo a 52 settimane	83,96 € - 63,04 €
Dividendi	No
Beta	0,85
Rapporto P/E	49,28
Rapporto PEG	-0,66
Rapporto P/B	4,65
Rapporto P/S	7,58

Profilo aziendale

Die Edwards Lifesciences Corporation bietet Produkte und Technologien für strukturelle Herzerkrankungen sowie für die Intensivpflege und chirurgische Überwachung in den Vereinigten Staaten, Europa, Japan und international an. Das Unternehmen bietet Transkatheter-Herzklappenersatzprodukte für den minimalinvasiven Ersatz von Herzklappen sowie Transkatheter-Herzklappenreparatur- und -ersatzprodukte zur Behandlung von Mitral- und Trikuspidalklappenerkrankungen. Das Unternehmen bietet auch die Transkatheter-Klappenreparatursysteme PASCAL und Cardioband für die minimal-invasive Therapie an. Darüber hinaus bietet es chirurgische strukturelle Herzlösungen an, wie z.B. eine chirurgische Aortenklappe unter dem Namen INSPIRIS; KONECT RESILIA, ein vormontiertes Aortenklappen-Gewebe-Conduit für Patienten, die einen Ersatz der Klappe, der Wurzel und der aufsteigenden Aorta benötigen; und das HARPOON Beating Heart Mitralklappen-Reparatursystem für Patienten mit degenerativer Mitralinsuffizienz. Darüber hinaus bietet das Unternehmen Lösungen für die Intensivpflege an, darunter fortschrittliche hämodynamische Überwachungssysteme zur Messung der Herzfunktion und des Flüssigkeitsstatus eines Patienten in der Chirurgie und auf der Intensivstation sowie die Software Acumen Hypotension Prediction Index, die Kliniker im Voraus warnt, wenn ein Patient einen gefährlich niedrigen Blutdruck entwickelt. Das Unternehmen vertreibt seine Produkte über ein Direktvertriebsnetz und unabhängige Vertriebshändler. Die Edwards Lifesciences Corporation wurde 1958 gegründet und hat ihren Hauptsitz in Irvine, Kalifornien.

Nome	Edwards Lifesciences
CEO	Bernard J. Zovighian
Sede centrale	Irvine, ca Stati Uniti
Sito web	edwards.com
Settore	Sanità
Industria	Biotecnologia
Quotazione in borsa	27/03/2000
Dipendenti	16.000